Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 189 entries
View as:

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04223856 Org: User:
Start: 03/30/20 End: 03/01/28 Due: 03/01/29

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Phase: N/A Priority: Normal
NCT ID: NCT01711814 Org: User:
Start: 09/26/12 End: 03/25/16 Due: 03/25/17

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine

Phase: N/A Priority: Normal
NCT ID: NCT02128321 Org: User:
Start: 01/31/14 End: 02/28/14 Due: 02/28/15

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Phase: N/A Priority: Normal
NCT ID: NCT02927262 Org: User:
Start: 01/10/17 End: 02/19/24 Due: 02/19/25

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05754333 Org: User:
Start: 08/02/23 End: 01/16/25 Due: 01/16/26

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01780844 Org: User:
Start: 03/05/13 End: 01/27/17 Due: 01/27/18

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02752035 Org: User:
Start: 08/01/16 End: 12/18/24 Due: 12/18/25

A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT02171143 Org: User:
Start: 04/30/12 End: 04/30/14 Due: 04/30/15

A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03760081 Org: User:
Start: 03/19/19 End: 10/16/20 Due: 10/16/21

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate

Phase: N/A Priority: Normal
NCT ID: NCT02698657 Org: User:
Start: 02/23/16 End: 09/07/17 Due: 09/07/18

A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02383368 Org: User:
Start: 03/23/15 End: 04/27/18 Due: 04/27/19

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Phase: N/A Priority: Normal
NCT ID: NCT03557931 Org: User:
Start: 07/13/18 End: 10/21/19 Due: 10/21/20

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT04277624 Org: User:
Start: 02/20/20 End: 02/26/21 Due: 02/26/22

Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Phase: N/A Priority: Normal
NCT ID: NCT03409081 Org: User:
Start: - End: - Due: -

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

Phase: N/A Priority: Normal
NCT ID: NCT04305184 Org: User:
Start: 09/10/20 End: 01/24/23 Due: 01/24/24

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Phase: N/A Priority: Normal
NCT ID: NCT02216214 Org: User:
Start: 10/07/14 End: 01/02/18 Due: 01/02/19

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility

Phase: N/A Priority: Normal
NCT ID: NCT03065959 Org: User:
Start: 06/28/17 End: 10/10/18 Due: 10/10/19

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

Phase: N/A Priority: Normal
NCT ID: NCT02194491 Org: User:
Start: 04/30/14 End: 05/31/16 Due: 05/31/17

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT02720263 Org: User:
Start: 03/28/16 End: 06/08/17 Due: 06/08/18

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT02723591 Org: User:
Start: 09/09/16 End: 06/14/19 Due: 06/14/20

A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause

Phase: N/A Priority: Normal
NCT ID: NCT05033886 Org: User:
Start: 11/08/21 End: 04/20/23 Due: 04/20/24

A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT04942964 Org: User:
Start: 09/13/21 End: 01/20/22 Due: 01/20/23

Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone

Phase: N/A Priority: Normal
NCT ID: NCT01597986 Org: User:
Start: 04/30/12 End: 06/30/12 Due: 06/30/13

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03505320 Org: User:
Start: 06/29/18 End: 02/28/27 Due: 02/28/28

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Phase: N/A Priority: Normal
NCT ID: NCT02113813 Org: User:
Start: 04/09/14 End: 02/11/19 Due: 02/11/20